Capital World Investors
ARTV

Capital World Investors’s Artiva Biotherapeutics ARTV Stock Holding History

Capital World Investors’s Portfolio ARTV Stock Details ARTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-866,622
Closed -$2.6M – 605
2025
Q1 		$2.6M Sell
866,622
-48,764
-5% -$263K ﹤0.01% 511
2024
Q4 		$9.23M Hold
915,386
– – ﹤0.01% 483
2024
Q3 		$14.1M Buy
+915,386
New +$10.6M ﹤0.01% 462

Other funds holding ARTV

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
VP
venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors's ARTV Position: Q2 2025 in Review

Capital World Investors sold out of Artiva Biotherapeutics (ARTV) in Q2 2025, closing a stake of 866,622 shares — an estimated $2.6M sold.

Capital World Investors first reported a position in ARTV in Q3 2024 and held it in 3 quarters. The position peaked at $14.1M in Q3 2024. 48 funds tracked by Wall St. Rank hold ARTV as of Q2 2025.

  • Capital World Investors reported no remaining Artiva Biotherapeutics position as of Q2 2025 after selling out during the quarter.
  • Capital World Investors sold 866,622 Artiva Biotherapeutics shares in Q2 2025, an estimated $2.6M.
  • Capital World Investors first reported a position in Artiva Biotherapeutics in Q3 2024 and held it in 3 quarters.
  • Capital World Investors's Artiva Biotherapeutics position peaked at $14.1M in Q3 2024.
  • 48 funds tracked by Wall St. Rank held Artiva Biotherapeutics as of Q2 2025.

Based on Capital World Investors's 13F filing for Q2 2025, filed 13 Aug 2025.